67 related articles for article (PubMed ID: 21044351)
1. Comprehensive Analysis of 29,464 Cancer Cases and 35,858 Controls to Investigate the Effect of the Cytotoxic T-Lymphocyte Antigen 4 Gene rs231775 A/G Polymorphism on Cancer Risk.
Wan H; Zhou H; Feng Y; Chen Y; Zhu L; Mi Y
Front Oncol; 2022; 12():878507. PubMed ID: 35600409
[TBL] [Abstract][Full Text] [Related]
2. Overview of Research on Germline Genetic Variation in Immune Genes and Cancer Outcomes.
Chao BN; Carrick DM; Filipski KK; Nelson SA
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):495-506. PubMed ID: 35027433
[TBL] [Abstract][Full Text] [Related]
3. Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Queirolo P; Dozin B; Morabito A; Banelli B; Piccioli P; Fava C; Leo C; Carosio R; Laurent S; Fontana V; Ferrucci PF; Martinoli C; Cocorocchio E; Battaglia A; Ascierto PA; Capone M; Simeone E; De Galitiis F; Pagani E; Antonini Cappellini GC; Marchetti P; Guida M; Tommasi S; Mandalà M; Merelli B; Quaglino P; Fava P; Guidoboni M; Romani M; Spagnolo F; Pistillo MP
Front Immunol; 2017; 8():386. PubMed ID: 28446908
[TBL] [Abstract][Full Text] [Related]
4. Associations between CTLA-4 +49 A/G (rs231775) polymorphism and cancer risk: a meta-analysis based on 52 case-control studies.
Wang L; Jiang Z; Qiu H; Tang W; Duan T; Wang L
Int J Clin Exp Med; 2015; 8(5):6835-51. PubMed ID: 26221222
[TBL] [Abstract][Full Text] [Related]
5. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
Ascierto PA; Grimaldi AM; Acquavella N; Borgognoni L; Calabrò L; Cascinelli N; Cesano A; Del Vecchio M; Eggermont AM; Faries M; Ferrone S; Fox BA; Gajewski TF; Galon J; Gnjatic S; Gogas H; Kashani-Sabet M; Kaufman HL; Larkin J; Lo RS; Mantovani A; Margolin K; Melief C; McArthur G; Palmieri G; Puzanov I; Ribas A; Seliger B; Sosman J; Suenaert P; Tarhini AA; Trinchieri G; Vidal-Vanaclocha F; Wang E; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2013 Jun; 11():137. PubMed ID: 23731854
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of polymorphism, hypermethylation and expression pattern of CTLA4 gene in a sample of Iranian patients with schizophrenia.
Kordi-Tamandani DM; Vaziri S; Dahmardeh N; Torkamanzehi A
Mol Biol Rep; 2013 Aug; 40(8):5123-8. PubMed ID: 23666060
[TBL] [Abstract][Full Text] [Related]
7. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.
Wang E; Zhao Y; Monaco A; Uccellini L; Kirkwood JM; Spyropoulou-Vlachou M; Panelli MC; Marincola FM; Gogas H
PLoS One; 2012; 7(7):e40805. PubMed ID: 22911710
[TBL] [Abstract][Full Text] [Related]
8. Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.
Wang XY; Zuo D; Sarkar D; Fisher PB
Expert Opin Pharmacother; 2011 Dec; 12(17):2695-706. PubMed ID: 22077831
[TBL] [Abstract][Full Text] [Related]
9. Anti-CTLA-4 antibody adjuvant therapy in melanoma.
Eggermont AM; Testori A; Maio M; Robert C
Semin Oncol; 2010 Oct; 37(5):455-9. PubMed ID: 21074060
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.
Gogas H; Dafni U; Koon H; Spyropoulou-Vlachou M; Metaxas Y; Buchbinder E; Pectasides E; Tsoutsos D; Polyzos A; Stratigos A; Markopoulos C; Panagiotou P; Fountzilas G; Castana O; Skarlos P; Atkins MB; Kirkwood JM
J Transl Med; 2010 Nov; 8():108. PubMed ID: 21044351
[TBL] [Abstract][Full Text] [Related]
12. A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon.
Pancoska P; Kirkwood JM; Bouros S; Spyropoulou-Vlachou M; Pectasides E; Tsoutsos D; Polyzos A; Markopoulos C; Panagiotou P; Castana O; Bafaloukos D; Fountzilas G; Gogas H
PLoS One; 2014; 9(1):e86375. PubMed ID: 24475110
[TBL] [Abstract][Full Text] [Related]
13. A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer.
Banelli B; Morabito A; Laurent S; Piccioli P; Dozin B; Ghio M; Ascierto PA; Monteghirfo S; Marasco A; Ottaviano V; Queirolo P; Romani M; Pistillo MP
Hum Immunol; 2014 Aug; 75(8):730-9. PubMed ID: 24801647
[TBL] [Abstract][Full Text] [Related]
14. Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.
Queirolo P; Morabito A; Laurent S; Lastraioli S; Piccioli P; Ascierto PA; Gentilcore G; Serra M; Marasco A; Tornari E; Dozin B; Pistillo MP
Cancer Invest; 2013 Jun; 31(5):336-45. PubMed ID: 23641913
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
